Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Global Blood Therapeutics' EU marketing application for Oxbryta (voxelotor) will undergo standard review once it is filed after the company failed to secure fast-track status for the sickle cell disease treatment. Only one product was granted accelerated assessment in October and November.